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Background: The most important action in the resuscitation of a newborn in the delivery room is to establish
effective assisted ventilation. The face mask and endotracheal tube are the devices used to achieve this goal.
Laryngeal mask airways that fit over the laryngeal inlet have been shown to be effective for ventilating newborns at
birth and should be considered as an alternative to facemask ventilation or endotracheal intubation among
newborns weighing >2,000 g or delivered ≥34 weeks’ gestation. A recent systematic review and meta-analysis of
supraglottic airways in neonatal resuscitation reported the results of four randomized controlled trials (RCTs) stating
that fewer infants in the group using laryngeal mask airways required endotracheal intubation (1.5%) compared to
the group using face masks (12.0%). However, there were methodological concerns over all the RCTs including the
fact that the majority of the operators in the trials were anesthesiologists.
Our hypothesis is based on the assumption that ventilating newborns needing positive pressure ventilation with a
laryngeal mask airway will be more effective than ventilating with a face mask in a setting where neonatal
resuscitation is performed by midwives, nurses, and pediatricians. The primary aim of this study will be to assess the
effectiveness of the laryngeal mask airway over the face mask in preventing the need for endotracheal intubation.
Methods/design: This will be an open, prospective, randomized, single center, clinical trial. In this study, 142
newborns weighing >1,500 g or delivered ≥34 weeks gestation needing positive pressure ventilation at birth will
be randomized to be ventilated with a laryngeal mask airway (LMA SupremeTM, LMA Company, UK - intervention
group) or with a face mask (control group). Primary outcome: Proportion of newborns needing endotracheal
intubation. Secondary outcomes: Apgar score at 5 minutes, time to first breath, onset of the first cry, duration of
resuscitation, death or moderate to severe hypoxic-ischemic encephalopathy within 7 days of life.
Trial registration: ClinicalTrials.gov identifier: NCT01963936 (October 11, 2013).
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The ability to maintain a patent airway and provide
effective positive pressure ventilation (PPV) is the main
objective of neonatal resuscitation [1,2]. This is currently
achieved with the use of a face mask (FM) or an endo-
tracheal tube (ETT). Both these devices have major limita-
tions from a strictly anatomical point of view and require
adequate operator skills. In certain situations, both FM* Correspondence: trevo@pediatria.unipd.it
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article, unless otherwise stated.ventilation and ETT intubation may prove difficult to es-
tablish an upper airway [3,4].
In 1981, Archie Brain designed the laryngeal mask air-
way (LMA) with the aim of producing an airway device
that would be more practical than the FM and less inva-
sive than the ETT [5].
In adults, the LMA is routinely used during anesthe-
siology procedures.
The potential advantages of the LMA over the FM in-
clude an easier insertion technique, less manipulation of
the patient’s head, neck, and jaw, a better airtight seal
after positioning, and more effective PPV [6]. Ease of
positioning and reduced invasiveness are the reportedntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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tube [6].
A recent study including 11,910 anesthesia pediatric
cases showed that only 102 cases (0.86%) experienced
LMA failure. Common presenting features of LMA
failures included leak (25%), obstruction (48%), and
patient intolerance such as intractable coughing/buck-
ing (11%) [7].
In the setting of the neonatal resuscitation, previous
observational studies showed that, when used by teams
with expertise (that is, anesthesiologists), the LMA pro-
vided effective PPV in most of the treated patients
(range 95 to 99%) [8-10]. A 2005 Cochrane review con-
cluded that there was no evidence to evaluate the safety
or efficacy for the use of LMA versus FM ventilation in
the resuscitation of newborn infants [11]. It suggested
that a well-designed randomized controlled trial (RCT)
comparing these two airway adjuncts was warranted
[11]. In 2013, a systematic review and meta-analysis of
supraglottic airways in neonatal resuscitation reported
the results of four RCTs, stating that fewer infants in the
LMA group required endotracheal intubation (1.5%) com-
pared to the FM group (12.0%) [12]. There were however,
methodological concerns over all the RCTs including the
fact that the majority of the operators in the trials were
anesthesiologists (who are less likely in most clinical set-
tings to be present at neonatal resuscitation).
The LMA is used more often by anesthesiologists ra-
ther than pediatricians, nurses, and midwives. It is thus
essential to demonstrate its effectiveness by those who
will be more commonly involved in neonatal resuscita-
tion in most clinical settings. Furthermore, it is import-
ant to thoroughly record any side effects, as in a case
series of a comparison of LMA over FM in infants in the
operating theatre, significantly more side effects were
reported using the LMA over the FM [13,14].
Although previous studies showed that the LMA was ef-
fective also in preterm infants weighing less than 2,000 g
[9,10], the last version of the International Guidelines for
Neonatal Resuscitation state that “a LMA should be con-
sidered during resuscitation if FM ventilation is unsuc-
cessful and tracheal intubation is unsuccessful or not
feasible. The LMA may be considered as an alternative to
a FM for PPV among newborns weighing >2,000 g or
delivered ≥34 weeks’ gestation” [1,2].
Despite this recommendation, it has not yet been shown
in a well-conducted RCT whether or not LMA is more
effective than FM in resuscitation of newborn infants.
Methods/design
Aim
The primary aim of this study will be to assess the
effectiveness of LMA over FM ventilation in preventing
the need for endotracheal intubation at birth.Study design
This is a single center, prospective, unblinded, randomized
clinical trial of LMA ventilation versus FM ventilation
in infants weighing >1,500 g or delivered ≥34 weeks’
gestation.
Inclusion criteria
Inborn infants satisfying the following inclusion criteria
will be eligible to participate in the study:
1. gestational age ≥34 weeks (and)
2. expected birth weight >1,500 g [9,10] (and)
3. need for PPV at birth; the need for PPV will be
determined by the presence of apnoea or gasping, or
heart rate <100 beats per minute (bpm) after initial
resuscitation measures (providing warmth,
positioning, clearing the airway, drying and
stimulation) over the first 30 seconds [1,2] (and)
4. parental consent; a written informed consent will be
obtained by a member of the neonatal team involved in




3. Major malformations of the respiratory system.
4. Congenital heart disease.
5. Stillbirths; a stillbirth will be diagnosed when a heart
rate is never established.
Primary outcome measure
The primary outcome of this study will be the proportion
of newborns needing endotracheal intubation.
Secondary outcome measures
1. Apgar score at 5 minutes.
2. Time to first breath, defined as the first respiratory
effort.
3. Time to first cry, defined as the first audible cry
spontaneously emitted by the infant.
4. Death or moderate to severe hypoxic-ischemic
encephalopathy (HIE) within 7 days of life, according
to a modification of Sarnat and Sarnat [15,16].
According to this classification, HIE grade I (mild)
includes irritability, hyperalertness, mild hypotonia,
and poor sucking; grade II (moderate) includes
lethargy, seizures, marked abnormalities of tone,
and requirement of tube feeding; grade III (severe)
includes coma, prolonged seizures, severe hypotonia,
and failure to maintain spontaneous respiration.
5. Complications secondary to the procedure.
6. Admission to NICU/normal nursery.
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The following data will be collected during resuscitation:
(1) Apgar score at 1 min after birth; (2) LMA insertion
time, the rate of successful insertion at the first
attempt, and the number of attempts required to in-
sert the LMA successfully; (3) adverse effects during
resuscitation.
Generalizability
The findings of this study will be important for other
units/settings in high as well low resource countries where
neonatal resuscitation is more often performed by pedia-
tricians, midwives, or nurses. Based on the results of the
present study, we could speculate whether a short-term
educational program on the LMA use will be effective in
the clinical practice; furthermore, we will be able to under-
stand whether personnel involved in neonatal resuscita-
tion should be trained to start resuscitation with an FM or
with an LMA. Finally, potential complications and side
effects due to the LMA will be strictly monitored and
collected.
Sample size
It is estimated that 5% of newborns receive resuscitation
with PPV [1,2]. Therefore, in C hospital, Hanoi, Vietnam
with more than 20,000 deliveries per year, approximately
1,000 patients will require resuscitation. Of these, about
90% (900 neonates) are newborns weighing >1,500 g or
delivered ≥34 weeks gestation.
The sample size was based on a previous study in which
the success rate of LMA and FM were 99% and 84%,
respectively [17]. To obtain a 90% power at a 0.05 level of
significance (one-sided), at least 58 subjects per group
need to be enrolled. The number of patients was increased
by 20% for each group considering the possibility of drop-
outs, leading to a final sample of 142 subjects.
Recruitment
Written and oral information will, whenever possible, be
offered to parents prior to the birth of their child if the
infant is likely to be eligible. Informed written consent will
be signed by a parent or guardian. A senior investiga-
tor will be available at all times to discuss concerns
raised by parents or clinicians during the course of
the trial.
Randomization
Eligible infants will be assigned to the LMA or the FM
group in a 1:1 ratio according to a computer-generated,
randomized sequence. The randomized allocation will be
concealed in double-enclosed, opaque, sealed, and sequen-
tially numbered envelopes prepared at the University
Hospital of Padua.In the delivery room or operating room, the next
sequential randomization envelope will be opened only
when the infant will be considered to be eligible by the
attending operator. The assigned procedure (PPV with
LMA or FM) will then be performed. Multiple births will
be separately randomized.Blinding
Due to the characteristics of the intervention, neither
caregivers nor outcome assessors will be masked to treat-
ment allocation. To minimize bias, strict criteria and defi-
nitions will be maintained during the trial.Guidelines for management
Before starting the study, all those involved in the neonatal
resuscitation participated in a one-day theoretical and
practical (manikin) course based on the Neonatal Resusci-
tation Program (NRP). During the course, one section was
dedicated to the preparation and insertion of the size 1 Su-
preme LMA™ [18]. In November 2011, three courses were
held by three certificated NRP teachers in collaboration
with an expert in the LMA use (DT). A total of 44 partici-
pants (15 physicians and 29 nurses) were trained.
After the course, a period of 3 months was left to rou-
tinely introduce LMA use in the delivery rooms. Five suc-
cessful LMA insertions in the manikin and three LMA
insertions in the clinical setting were required to all partic-
ipants before starting the study.
The American Heart Association and American Acad-
emy of Pediatrics Guidelines for Neonatal Resuscitation
will be followed in this study [1,2]. After initial steps
(warming, clearing airway, drying, stimulation), PPV with
FM or LMA and bag will be initiated in the case of apnea
and/or gasping and/or heart rate < 100 bpm. The neo-
nate’s trachea will be intubated if the heart rate does not
rise or remains less than 60 bpm after 30 seconds of
PPV with the LMA or FM. A maximum of three at-
tempts for obtaining effective PPV with an LMA or an
FM will be allowed.
Manual ventilation will be initiated in room air at a
frequency of 40 to 60 breaths per minute [1,2]. The FiO2
will be increased to 1,0 (flow rate 6 to 8 L/min) in case
of persistent cyanosis and/or heart rate <100 bpm after
90 seconds from the beginning of PPV. At least two
trained people involved in the study will take part in the
resuscitation of all enrolled patients.
Resuscitation will start immediately after delivery of
the infant, when a stop watch will be switched on by
one of the members of the resuscitation team.
The duration of resuscitation will be defined as the
time period from starting resuscitation to the establish-
ment of a spontaneous and sustained respiratory pattern
of efficacious respiratory movements, which allowed the
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and respiratory rate).
In this study, the last model of size 1 LMA Supreme
(LMA Supreme™, LMA Company, UK) will be used [18].
Previous studies conducted in adult patients showed the
efficacy and the safety of the LMA Supreme [19,20]. The
LMA Supreme is superior to the LMA Classic™ with re-
gard to insertion time and oropharyngeal seal pressure
[21]; a further advantage consists in the gastric access.
A previous neonatal manikin study confirmed these
findings, including a higher level of satisfaction expressed
by users [22].
Data collection
Data will be recorded from clinical records and from a
data sheet designed for this study, where all the data ob-
tained during resuscitation procedures will be collected
by an observer not involved in the resuscitation maneu-
vers. Registered clinical information will be: eligibility,
antenatal history, randomization, and all data above listed
in the ‘Primary outcome measure’, ‘Secondary outcome
measures’ and ‘Other collected data’ sections. Further in-
formation will be collected on expected serious adverse
events (SAEs).
Statistical analysis
Categorical data will be expressed as number and percent-
age and compared using Fisher’s test. Continuous data will
be expressed as mean and standard deviation or median
and interquartile range. The normality assumption of con-
tinuous variables will be evaluated using Shapiro-Wilk
test. Continuous data will be compared using Student’s
t-test or the Mann-Whitney non-parametric test. Correl-
ation between continuous data will be evaluated using the
Pearson correlation coefficient or the Spearman correl-
ation coefficient. A P-value less than 0.05 will be consid-
ered significant. Statistical analysis will be performed
using the R 2.12 language [23].
Duration of study
In this study, 142 infants will be recruited. The trial will
terminate when the last recruited infant is discharged
from hospital, or dies.
Ethics committee approval
The C hospital, Hanoi, Vietnam Ethis Committees for Hu-
man Investigation approved the study (SO:901/QD-PSTW;
Ha Noi, 9 August 2012).
Compliance to protocol
Compliance will be defined as full adherence to protocol.
Compliance with the protocol will be ensured by two
members of the project (TDC, NTTH) responsible for
local data collection. They will weekly monitor theadherence to the study protocol and will input the pa-
tients’ data in an Excel data sheet.
Safety
Safety measures will include incidence, severity, and
causality of reported SAEs, represented by changes in
occurrence of the expected common neonatal complica-
tions and the development of unexpected SAEs. All
SAEs will be followed until complete resolution or until
the clinician responsible for the care of the recruited
patient considers the event to be chronic or the infant to
be stable. If there is a reasonable suspected causal rela-
tionship with the intervention, SAEs will be reported to
the Ethics Committee to guarantee the safety of the
participants.
Discussion
There are unique features of this trial compared to prior
studies on the use of the LMA during neonatal resusci-
tation. To our knowledge, three randomized controlled
trials including 140 patients have been previously pub-
lished [12]. Due to the limited number of enrolled
patients, a final conclusion cannot be drawn. A further
trial with a different study design (quasi- randomized
controlled trial) showed that the LMA significantly re-
duced the need of intubation in the delivery room in
comparison with FM ventilation [17]. All these studies
were performed with a classic LMA. In this trial, we used,
for the first time, a more advanced model of LMA, the
LMA Supreme.
Trial status
The trial is currently recruiting study subjects.
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